184 related articles for article (PubMed ID: 31100004)
1. Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor.
Fontana F; Fusciello M; Groeneveldt C; Capasso C; Chiaro J; Feola S; Liu Z; Mäkilä EM; Salonen JJ; Hirvonen JT; Cerullo V; Santos HA
ACS Nano; 2019 Jun; 13(6):6477-6490. PubMed ID: 31100004
[TBL] [Abstract][Full Text] [Related]
2. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
3. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
4. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells.
Verbeke R; Lentacker I; Breckpot K; Janssens J; Van Calenbergh S; De Smedt SC; Dewitte H
ACS Nano; 2019 Feb; 13(2):1655-1669. PubMed ID: 30742405
[TBL] [Abstract][Full Text] [Related]
5. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
[TBL] [Abstract][Full Text] [Related]
6. Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality.
Kang T; Huang Y; Zhu Q; Cheng H; Pei Y; Feng J; Xu M; Jiang G; Song Q; Jiang T; Chen H; Gao X; Chen J
Biomaterials; 2018 May; 164():80-97. PubMed ID: 29499438
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
Luo Z; Wang C; Yi H; Li P; Pan H; Liu L; Cai L; Ma Y
Biomaterials; 2015 Jan; 38():50-60. PubMed ID: 25457983
[TBL] [Abstract][Full Text] [Related]
9. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy.
Hu X; Wu T; Qin X; Qi Y; Qiao Q; Yang C; Zhang Z
Adv Healthc Mater; 2019 Jan; 8(1):e1800837. PubMed ID: 30506847
[TBL] [Abstract][Full Text] [Related]
10. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
11. Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy.
Zhao H; Xu J; Li Y; Guan X; Han X; Xu Y; Zhou H; Peng R; Wang J; Liu Z
ACS Nano; 2019 Nov; 13(11):13127-13135. PubMed ID: 31710460
[TBL] [Abstract][Full Text] [Related]
12. Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
Wakabayashi R; Sakuragi M; Kozaka S; Tahara Y; Kamiya N; Goto M
Mol Pharm; 2018 Mar; 15(3):955-961. PubMed ID: 29397746
[TBL] [Abstract][Full Text] [Related]
13. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.
Bocanegra Gondan AI; Ruiz-de-Angulo A; Zabaleta A; Gómez Blanco N; Cobaleda-Siles BM; García-Granda MJ; Padro D; Llop J; Arnaiz B; Gato M; Escors D; Mareque-Rivas JC
Biomaterials; 2018 Jul; 170():95-115. PubMed ID: 29656235
[TBL] [Abstract][Full Text] [Related]
14. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators.
Conniot J; Scomparin A; Peres C; Yeini E; Pozzi S; Matos AI; Kleiner R; Moura LIF; Zupančič E; Viana AS; Doron H; Gois PMP; Erez N; Jung S; Satchi-Fainaro R; Florindo HF
Nat Nanotechnol; 2019 Sep; 14(9):891-901. PubMed ID: 31384037
[TBL] [Abstract][Full Text] [Related]
15. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
16. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
17. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
18. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
20. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
Molino NM; Neek M; Tucker JA; Nelson EL; Wang SW
Biomaterials; 2016 Apr; 86():83-91. PubMed ID: 26894870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
